J.Thaddeus Beck, MD, FACP is a medical oncologist at Highlands Oncology located in Rogers, Arkansas. 

, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with J. Thaddeus Beck, MD, FACP, about the 

FDA approval of pembrolizumab and berahyaluronidase alfa-pmph

 (subcutaneous pembrolizumab; Keytruda Qlex) for subcutaneous injection in adult and pediatric patients at least 12 years of age with solid tumors for which the intravenous formulation of pembrolizumab (Keytruda) is indicated. Dr Beck is a medical oncologist at Highlands Oncology in Rogers, Arkansas.

In our exclusive interview, Dr Beck discussed the significance of this approval, key findings from the pivotal phase 3 3475A-D77 study (NCT05722015), and ways that this new formulation may improve patient-centered care.

That’s all we have for today! Thank you for listening to this episode of 

. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit 

 is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

Beck on the FDA Approval of Subcutaneous Pembrolizumab in Solid Tumors

“The approval of the subcutaneous form of pembrolizumab gives us another option that we can use to tailor treatments to [each] patient’s individual situation.”

J. Thaddeus Beck, MD, FACP, a medical oncologist at Highlands Oncology Group, discussed the clinical significance of the

FDA approval of subcutaneous pembrolizumab and berahyaluronidase alfa-pmph

 (Keytruda Qlex) for use across all adult and pediatric (aged ≥12 years) solid tumor indications already authorized for intravenous (IV) pembrolizumab.

The regulatory decision was supported by findings from the open-label, phase 3 3475A-D77 study (NCT05722015). Subcutaneous pembrolizumab given with chemotherapy showed noninferior pharmacokinetics vs IV pembrolizumab plus chemotherapy in patients with metastatic non–small cell lung cancer, meeting predefined acceptance margins for cycle 1 AUC

and cycle 3 (steady-state) trough concentration.

Efficacy and safety were comparable between arms. The subcutaneous regimen induced an objective response rate of 45% (95% CI, 39%-52%) vs 42% (95% CI, 33%-51%) with the IV formulation. No meaningful differences in progression-free survival or overall survival were noted between the formulations, and no new safety signals were observed.

Beck emphasized the practical advantages of the subcutaneous formulation, stating that the subcutaneous injection is administered in minutes rather than over half an hour, thus reducing chair time. He added that in the study’s sequential-exposure design, where patients experienced both administration routes before choosing a preferred approach, the clear majority opted to continue subcutaneous dosing, citing shorter visits and lower treatment burden.

From a clinical standpoint, Beck added that subcutaneous pembrolizumab enables treatment individualization without compromising pharmacokinetic exposure, antitumor activity, or tolerability. The option may improve patient throughput in high-volume clinics, streamline care for those with transportation or scheduling constraints, and maintain continuity of immune checkpoint therapy across the same disease settings as IV pembrolizumab.

Beck concluded that the availability of a subcutaneous formulation broadens delivery choices and preserves the clinical profile of pembrolizumab, aligning immunotherapy with patient-centered, operationally efficient care.

Videos

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab and berahyaluronidase for use across all adult and solid-tumor indications.

J.Thaddeus Beck, MD, FACP

Articles

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

Dr Beck on the FDA Approval of Subcutaneous Pembrolizumab in Solid Tumors